🇺🇸 FDA

Company profile · Sponsor

VACCINEX,

VACCINEX, INC.

VCNX · NYSE pharma ROCHESTER, NY, USA
Pipeline
11
Drugs
0
Patents
8

Quick answer

VACCINEX, (VCNX) is a pharma company. headquartered in ROCHESTER, NY, USA. listed on NYSE. NovaPharmaNews links 11 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker VCNX
Exchange NYSE
Company type pharma
Headquarters ROCHESTER, NY, USA
SEC CIK 0001205922

Pipeline (11)

Search pipeline →

  1. Avelumab and Pepinemab

    VACCINEX,

    Metastatic Pancreatic Adenocarcinoma

    phase 2 small molecule active

    1 trial

  2. VX15/2503

    VACCINEX,

    Huntington's Disease

    phase 2 small molecule completed

    1 trial

  3. VX15/2503 + avelumab

    VACCINEX,

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule completed

    1 trial

  4. pepinemab + pembrolizumab

    VACCINEX,

    Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)

    phase 2 small molecule completed

    1 trial

  5. Anti-SEMA4D Monoclonal Antibody VX15/2503

    VACCINEX,

    Colon Carcinoma Metastatic in the Liver

    phase 1 mab completed

    1 trial

  6. Anti-SEMA4D Monoclonal Antibody VX15/2503

    VACCINEX,

    Metastatic Melanoma

    phase 1 mab terminated

    1 trial

  7. Dendritic Cell (DC1) Vaccine

    VACCINEX,

    HER2-positive Breast Cancer

    phase 1 mab active

    1 trial

  8. Ipilimumab

    VACCINEX,

    Pathologic Stage IIIB Cutaneous Melanoma AJCC v8

    phase 1 mab active

    1 trial

  9. VX15/2503

    VACCINEX,

    Multiple Sclerosis

    phase 1 small molecule completed

    1 trial

  10. VX15/2503

    VACCINEX,

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  11. VX15/2503

    VACCINEX,

    Squamous Cell Carcinoma of the Head and Neck

    phase 1 mab active

    1 trial

Patents (8)

Search patents →

  1. US 12201719

    Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12070500

    Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasis

    Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12006365

    Human anti-semaphorin 4D antibody

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12006364

    Anti-CD100 antibodies and methods for using the same

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11981730

    Anti-CXCL13 antibodies and methods of using the same

    Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11859000

    Anti-CCR8 antibodies and uses thereof

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11660330

    Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy

    Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11597765

    Use of semaphorin-4D binding molecules for the treatment of Rett syndrome

    Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is VACCINEX,?

VACCINEX, (VCNX) is a pharma company. headquartered in ROCHESTER, NY, USA. listed on NYSE. NovaPharmaNews links 11 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does VACCINEX, sponsor?

We track 11 ClinicalTrials.gov-linked programs for VACCINEX,, including Avelumab and Pepinemab and 10 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does VACCINEX, company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.